Original articleApremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis
Key words
Abbreviations used
Cited by (0)
Sponsored by Celgene Corporation. The authors received editorial support in the preparation of the manuscript from Kathy Covino, PhD, of Peloton Advantage, LLC, funded by Celgene Corporation.
Disclosure: Dr Bissonnette has received honoraria for participation on advisory boards and/or research grants from AbbVie, Amgen, Celgene Corporation, Eli Lilly, Galderma Laboratories, Incyte, Janssen, Kineta, LEO Pharma US, Merck, Novartis Pharmaceuticals, Pfizer, and Tribute. Dr Pariser or his institution has received grant/research support from Abbott Laboratories, Amgen, Astellas Pharma US, Asubio Pharmaceuticals, Basilea Pharmaceutical, Celgene Corporation, Dow Pharmaceutical Sciences, Eli Lilly, Galderma Laboratories, Graceway Pharmaceuticals, Intendis, Johnson & Johnson, Novartis Pharmaceuticals, Novo Nordisk A/S, Ortho Dermatologics, Photocure ASA, Stiefel Laboratories, and Valeant Pharmaceuticals, and has received other financial support from LEO Pharma US and Pfizer. Dr Wasel has served as an investigator for Celgene Corporation. Drs Goncalves, Day, and Chen are employees of Celgene Corporation. Dr Sebastian has received research grants from Celgene Corporation.
Reprints not available from the authors.